Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Drops Phase II Glaucoma Candidate

This article was originally published in The Pink Sheet Daily

Executive Summary

Drug maker remains committed to joint research program with NicOx, however, and will proceed with follow-up compounds.

You may also be interested in...



NicOx Buys Back Glaucoma Drug Rights From Pfizer

The French biotech looks to deal the drug even as it continues to focus on the development of its other main asset, the still unpartnered naproxcinod for osteoarthritis.

NicOx Buys Back Glaucoma Drug Rights From Pfizer

The French biotech looks to deal the drug even as it continues to focus on the development of its other main asset, the still unpartnered naproxcinod for osteoarthritis.

NicOx Envisions Co-Commercialization And In-Licensing Strategy Around Naproxcinod

French firm plans to build U.S. sales force to market osteoarthritis drug and complementary products it will acquire or license.

Related Content

Topics

UsernamePublicRestriction

Register

PS067857

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel